Recent and accumulating evidence from epidemiological, proteomics, cell culture and animal model studies indicate a neuroprotective role for apoA-I in AD, whereby apoA-I modulates AD risk, severity and the rate of cognitive decline. This evidence concerns the gene APOA1 and Alzheimer disease.